| abstract |
The invention relates to pharmaceutical compositions comprising a monoclonal antibody labeled with a radionuclide against CD38, and methods for treating hematological malignancy, inhibition of growth and / or proliferation of a cell expressing CD38, or treating a disease or disorder involving cells expressing CD38. An example of a monoclonal antibody comprises actinium-labeled daratumumab (225Ac). |